- Home
- CERO vs SONN Comparison
CERO vs SONN Comparison
Compare CERO & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- SONN
- Stock Information
- Founded
- CERO 2017
- SONN N/A
- Country
- CERO United States
- SONN United States
- Employees
- CERO 8
- SONN N/A
- Industry
- CERO
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- CERO
- SONN Health Care
- Exchange
- CERO Nasdaq
- SONN Nasdaq
- Market Cap
- CERO 3.7M
- SONN 3.8M
- IPO Year
- CERO N/A
- SONN N/A
- Fundamental
- Price
- CERO $0.45
- SONN $1.25
- Analyst Decision
- CERO Buy
- SONN Strong Buy
- Analyst Count
- CERO 2
- SONN 1
- Target Price
- CERO $3.00
- SONN $20.00
- AVG Volume (30 Days)
- CERO 993.4K
- SONN 39.8K
- Earning Date
- CERO 05-15-2025
- SONN 05-13-2025
- Dividend Yield
- CERO N/A
- SONN N/A
- EPS Growth
- CERO N/A
- SONN N/A
- EPS
- CERO N/A
- SONN N/A
- Revenue
- CERO N/A
- SONN $1,000,000.00
- Revenue This Year
- CERO N/A
- SONN $5,376.22
- Revenue Next Year
- CERO N/A
- SONN N/A
- P/E Ratio
- CERO N/A
- SONN N/A
- Revenue Growth
- CERO N/A
- SONN 978.39
- 52 Week Low
- CERO $0.40
- SONN $1.08
- 52 Week High
- CERO $102.00
- SONN $16.00
- Technical
- Relative Strength Index (RSI)
- CERO 35.19
- SONN 51.70
- Support Level
- CERO $0.42
- SONN $1.13
- Resistance Level
- CERO $0.50
- SONN $1.21
- Average True Range (ATR)
- CERO 0.05
- SONN 0.08
- MACD
- CERO 0.00
- SONN 0.00
- Stochastic Oscillator
- CERO 24.77
- SONN 56.67
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.